We summarized data showing that FT-Is in combination with TKIs, Omacetaxine, AURK-Is and JAK2-Is have demonstrated efficacy in CML patients. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.